Giulia Tasca

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Nicoletta Colombo, Elena Biagioli, Kenichi Harano et al. · The Lancet Oncology · 2024 · 114 citations

Medicine, Oncology, Pharmacotherapy +7

Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia

Antonella Teramo, Cristina Gattazzo, Francesca Passeri et al. · Blood · 2013 · 104 citations

Medicine, Cancer Biology, Oncology +10

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy

Maria Vittoria Dieci, Gaia Griguolo, Michele Bottosso et al. · npj Breast Cancer · 2021 · 98 citations · Full text

Medicine, Oncology, Breast Oncology +16

Immune characterization of breast cancer metastases: prognostic implications

Maria Vittoria Dieci, Vassilena Tsvetkova, Enrico Orvieto et al. · Breast Cancer Research · 2018 · 89 citations · Full text

Medicine, Immunology, Oncology +17

Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy

Maria Vittoria Dieci, Vassilena Tsvetkova, Gaia Griguolo et al. · European Journal of Cancer · 2020 · 74 citations · Full text

Life Sciences, Immunology, Oncology +17